Literature DB >> 23529275

Can HMGI-C be used as an aid with MDM2 and CDK4 to differentiate liposarcoma subtypes from their mimics?

Hanan Alshenawy1.   

Abstract

PURPOSE: Liposarcoma represents the most common soft tissue tumors in adults. The tumors are characterized by a high morphological diversity and a great variation in biological behavior. Atypical lipomatous tumors represent a distinctive subset of mesenchymal neoplasms featuring mature adipocytic differentiation. Histologically, atypical lipomatous tumor might be easily confused with lipoma. Conversely, dedifferentiated liposarcoma may be confused with other spindle cell/pleomorphic undifferentiated tumors.
METHODS: A group of liposarcomas was analyzed by investigating the MDM2, CDK4, and HMGI-C proteins. The study was extended to a group of lipomas and non-lipomatous sarcomas, to determine whether the immunohistochemical investigation of these proteins might play any diagnostic role.
RESULTS: Our data suggest that ordinary lipomas may form a molecular genetic and morphological continuum with atypical lipomatous tumor. At one end of the spectrum are lipomas characterized by HMGI-C activation and at the other end are atypical lipomatous tumors with overrepresentation of the HMGI-C, CDK4, or MDM2 proteins. These findings not only provide insights into the molecular pathogenesis of lipomatous tumors, but also indicate that the immunohistochemical analysis of HMGI-C, CDK4, or MDM2 may help to increase diagnostic accuracy.
CONCLUSIONS: HMGI-C is a useful adjunct in the diagnosis of atypical lipomatous tumor and dedifferentiated liposarcoma and differentiates them from their mimics. Therefore, in our experience, HMGI-C expression alone is of rather limited value in the differential diagnosis of liposarcoma subtypes.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23529275     DOI: 10.1007/s00432-013-1420-6

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  23 in total

1.  MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data.

Authors:  Matthieu Bui Nguyen Binh; Xavier Sastre-Garau; Louis Guillou; Gonzague de Pinieux; Philippe Terrier; Réal Lagacé; Alain Aurias; Isabelle Hostein; Jean Michel Coindre
Journal:  Am J Surg Pathol       Date:  2005-10       Impact factor: 6.394

2.  Coordinated expression and amplification of the MDM2, CDK4, and HMGI-C genes in atypical lipomatous tumours.

Authors:  A P Dei Tos; C Doglioni; S Piccinin; R Sciot; A Furlanetto; M Boiocchi; P Dal Cin; R Maestro; C D Fletcher; G Tallini
Journal:  J Pathol       Date:  2000-04       Impact factor: 7.996

3.  Reproducibility of MDM2 and CDK4 staining in soft tissue tumors.

Authors:  Matthieu Bui Nguyen Binh; Xavier Sastre Garau; Louis Guillou; Alain Aurias; Jean-Michel Coindre
Journal:  Am J Clin Pathol       Date:  2006-05       Impact factor: 2.493

4.  Co-amplification and overexpression of CDK4, SAS and MDM2 occurs frequently in human parosteal osteosarcomas.

Authors:  J S Wunder; K Eppert; S R Burrow; N Gokgoz; R S Bell; I L Andrulis; N Gogkoz
Journal:  Oncogene       Date:  1999-01-21       Impact factor: 9.867

5.  Primary retroperitoneal myxoid/round cell liposarcoma is a nonexisting disease: an immunohistochemical and molecular biological analysis.

Authors:  Ronald S A de Vreeze; Daphne de Jong; Ivon H G Tielen; Henrique J Ruijter; Petra M Nederlof; Rick L Haas; Frits van Coevorden
Journal:  Mod Pathol       Date:  2008-09-26       Impact factor: 7.842

Review 6.  Diagnosis and management of lipomatous tumors.

Authors:  Kimberly Moore Dalal; Cristina R Antonescu; Samuel Singer
Journal:  J Surg Oncol       Date:  2008-03-15       Impact factor: 3.454

7.  Can MDM2 and CDK4 make the diagnosis of well differentiated/dedifferentiated liposarcoma? An immunohistochemical study on 129 soft tissue tumours.

Authors:  P B Aleixo; A A Hartmann; I C Menezes; R T Meurer; A M Oliveira
Journal:  J Clin Pathol       Date:  2009-12       Impact factor: 3.411

8.  Clinical and biological significance of CDK4 amplification in well-differentiated and dedifferentiated liposarcomas.

Authors:  Antoine Italiano; Laurence Bianchini; Elisabet Gjernes; Frédérique Keslair; Dominique Ranchere-Vince; Jean-Marc Dumollard; Juliette Haudebourg; Agnès Leroux; Claire Mainguené; Philippe Terrier; Frédéric Chibon; Jean-Michel Coindre; Florence Pedeutour
Journal:  Clin Cancer Res       Date:  2009-09-08       Impact factor: 12.531

9.  Detection of MDM2 gene amplification or protein expression distinguishes sclerosing mesenteritis and retroperitoneal fibrosis from inflammatory well-differentiated liposarcoma.

Authors:  Joshua Weaver; John R Goldblum; Sondra Turner; Raymond R Tubbs; Wei-Lein Wang; Alexander Jf Lazar; Brian P Rubin
Journal:  Mod Pathol       Date:  2008-10-03       Impact factor: 7.842

10.  Prognostic factors and expression of MDM2 in patients with primary extremity liposarcoma.

Authors:  Rosalvo Zósimo Bispo Júnior; Olavo Pires de Camargo; Cláudia Regina G C M de Oliveira; Renée Zon Filippi; André Mathias Baptista; Marcelo Tadeu Caiero
Journal:  Clinics (Sao Paulo)       Date:  2008-04       Impact factor: 2.365

View more
  2 in total

Review 1.  Retroperitoneal liposarcoma: current insights in diagnosis and treatment.

Authors:  Lucas E Matthyssens; David Creytens; Wim P Ceelen
Journal:  Front Surg       Date:  2015-02-10

2.  Expression of FRS2 in atypical lipomatous tumor/well-differentiated liposarcoma and dedifferentiated liposarcoma: an immunohistochemical analysis of 182 cases with genetic data.

Authors:  Wenyi Jing; Ting Lan; Yan Qiu; Ran Peng; Yang Lu; Huijiao Chen; Min Chen; Xin He; Chen Chen; Hongying Zhang
Journal:  Diagn Pathol       Date:  2021-10-25       Impact factor: 2.644

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.